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S pontaneous pregnancy loss occurs in approxi-mately 15-25% of pregnancies [1].  Recurrent 
pregnancy loss (RPL) is a disorder defined by two or 
more failed clinical pregnancies [1].  Fewer than 5% of 
women experience 2 consecutive miscarriages,  and only 
1% experience 3 or more [1 , 2].  The Practice Commit-
tee of the American Society for Reproductive Medicine 
recommends that evaluation of RPL should proceed 
after 2 consecutive clinical pregnancy losses [1].  Poten-
tial causes of RPL include parental chromosomal 
abnormalities,  untreated hypothyroidism,  uncontrolled 
diabetes mellitus,  certain uterine anatomic abnormali-
ties,  antiphospholipid antibody syndrome (APS) [3],  
heritable and/or acquired thrombophilias,  immuno-
logic abnormalities,  infections,  and environmental 
factors; however,  in 50% to 75% of women with RPL,  
no causative factors are identified [1 , 3].
The association between acquired/inherited throm-
bophilias and pregnancy loss has been well established 
[1 , 3 , 4].  APS is known to be the most frequent risk 
factor associated with RPL in women with acquired 
thrombophilias [3].  Although the underlying patho-
physiological mechanisms are not well known,  throm-
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Thrombosis in decidual vessels is one of the mechanisms of pregnancy loss.  However,  few studies have assessed 
the relation between platelet activation,  which is known to cause of thrombosis,  and recurrent pregnancy loss 
(RPL).  We investigated platelet activation in women with RPL compared to controls by measuring plasma levels 
of platelet factor 4 (PF4) and β-thromboglobulin (βTG),  and assessed correlations between PF4/βTG and coag-
ulative risk factors associated with RPL.  The study group included 135 women who had experienced two or 
more consecutive pregnancy losses.  The control group included 28 age-matched healthy women who had never 
experienced pregnancy loss.  PF4 and βTG plasma levels were significantly higher in the women with RPL than 
controls (PF4: 14.0 [8.0-20.0] vs. 9.0 [6.0-12.0] ng/ml,  p= 0.043; βTG: 42.0 [24.3-59.8] vs. 31.5 [26.6-36.4] ng/ml,  
p= 0.002).  There was a significant association between βTG and anti-phosphatidylethanolamine antibody 
immunoglobulin M (aPE IgM) (p= 0.048).  Among the women with RPL,  18 of those who were positive for PF4 
(45%) and 18 of those who were positive for βTG (37%) were negative for all known coagulative risk factors 
associated with RPL.  Measurements of PF4 and βTG may be important because they help identify women who 
are at risk of RPL.
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bophilias have been considered to be related to throm-
bosis in decidual vessels or impairment of placentation 
through hypercoagulability and inflammation [4].  
Indeed,  it has long been hypothesized that women with 
RPL are already in a prothrombotic state before preg-
nancy begins [5].  Moreover,  an exaggerated hemo-
static response is known to lead to thrombosis in decid-
ual vessels and placentation defects in some cases of 
RPL [5 , 6].
Two of the known thrombosis-specific proteins,  
platelet factor 4 (PF4) and β-thromboglobulin (βTG) are 
chemokines released from α-granules in platelets when 
the platelets are activated during the release reaction 
induced by ADP,  epinephrine,  arachidonic acid,  colla-
gen,  and thrombin [7].  PF4 and βTG are elevated in the 
plasma of prethrombotic and thrombotic patients,  and 
are considered to reflect in vivo platelet activation in 
these patients [7].  Elevated plasma levels of PF4 and 
βTG have been reported in patients with cardiovascular 
and thrombotic diseases such as atherosclerosis,  isch-
emic heart diseases and diabetes mellitus with vascu-
lopathy [8-12],  and inflammatory diseases such as 
rheumatic diseases,  atopic dermatitis,  asthma and 
inflammatory bowel diseases [13-17].  However,  to our 
knowledge there have been no studies investigating PF4 
and βTG in the setting of RPL.
The purpose of this study was to determine whether 
or not women with RPL were in a stage of platelet acti-
vation.  We measured the plasma levels of PF4 and βTG 
in women with RPL and compared them to those in 
healthy women who had never experienced pregnancy 
losses.  We also assessed whether there was any correla-
tion between PF4/βTG levels and the known coagula-
tive risk factors associated with RPL.
Materials and Methods
This study was carried out at the Department of 
Obstetrics and Gynecology of Okayama University 
Hospital over a period of 5 years (January 2010- 
December 2014).  The study was approved by the ethics 
committee of Okayama University Graduate School of 
Medicine,  Dentistry and Pharmaceutical Sciences and 
Okayama University Hospital (approval no.963).  
Explicit or opt-out consents were collected from each 
participant in conformity with the decisions of the eth-
ics committee.  The study group included 135 women 
who had experienced two or more consecutive preg-
nancy losses (pregnancy at < 12 weeks,  not including 
biochemical pregnancy).  The control group consisted 
of 28 age-matched multiparous healthy women who had 
not had a previous pregnancy loss.  All subjects in both 
groups showed no abnormal findings in physical exams 
and pelvic ultrasound tests.  Women were excluded 
from both groups if they declined enrollment,  were 
younger than 20 years old or older than 43 years old,  
and/or had chronic diseases such as hypertension,  dia-
betes mellitus,  renal diseases,  infectious digestive dis-
eases,  other gynecologic problems (endometriosis,  
evident uterine anatomic abnormality,  uterine fibroids,  
adenomyosis,  uterine polyps and cervical incompe-
tence).  Women or women whose partners had been 
examined for and found to have chromosomal abnor-
malities causative of miscarriage were also excluded.  
Finally,  we excluded women who had a history of 
thrombotic diseases,  smoking,  or use of medications 
affecting platelet functions,  such as hormonal treat-
ments,  aspirin,  other nonsteroidal anti-inflammatory 
drugs and anticoagulant drugs.  All subjects were exam-
ined at least 3 months after previous pregnancies.
Measurement of PF4 and βTG levels. Venous 
blood samples were collected by single puncture and 
aspiration at a regular speed using a 20-gauge needle 
without a tourniquet.  Samples were placed immedi-
ately on ice for 15 to 30 min.  Blood samples were cen-
trifuged at 2,000 g for 30 min at 4°C.  Plasma samples 
were obtained from directly under the supernatant by a 
micropipette,  then stored at −80°C in a refrigerator 
until analysis.  Plasma levels of PF4 and βTG were mea-
sured by enzyme immune assay (EIA) (SRL,  Tokyo).  
The reference values of PF4 and βTG were defined as 
< 20 ng/ml and < 50 ng/ml,  respectively,  which are the 
normal ranges provided by the manufacturer.
Measurement of coagulative risk factors in RPL.
We performed blood tests in the RPL group as follows.  
The dilute Russell viper venom test was performed to 
measure lupus anticoagulant (LAC) (BML,  Tokyo) in 
RPL.  The levels of anti-phospholipid antibodies (aPA),  
including anti-cardiolipin antibody immunoglobulin G 
(aCL IgG),  anti-cardiolipin antibody immunoglobulin 
M (aCL IgM),  anti-phosphatidylethanolamine antibody 
immunoglobulin G (aPE IgG) and anti-phosphatidy-
lethanolamine antibody immunoglobulin M (aPE IgM),  
were measured in the women with RPL by enzyme-
linked immunosorbent assay (ELISA) (SRL).  To diag-
nose protein S deficiency,  we measured protein S activ-
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ity by enzyme immunoassay (EIA) (BML) and/or 
protein S antigen by EIA (SRL).  We defined protein S 
deficiency as protein S activity and/or protein S antigen 
of less than 60%.  Protein C activity was measured by 
the synthetic substrate method (LSI,  Tokyo).  Protein C 
deficiency was defined as protein C activity of less than 
60%.  Coagulation factors XII (FXII) were measured by 
the coagulation time method (SRL) to evaluate FXII 
deficiency.  We defined FXII deficiency as a plasma FXII 
level of less than 60%.
Statistical analysis. Continuous variables are 
expressed as the median and interquartile range if not 
noted otherwise.  Student’s t-test and Mann-Whitney U 
test were used to compare differences between the 
groups.  A chi-square test was used to indicate correla-
tions between variables.  All analyses were performed 
using the software package IBM SPSS Statistics,  ver. 20.  
Significance was established at the p < 0.05 level.
Results
PF4 and βTG in the RPL and control groups.
Characteristics and clinical findings of participants are 
shown in Table 1.  There were no statistically significant 
differences between subjects of the control and RPL 
groups in regard to age and body mass index (BMI).
Plasma levels of PF4 in the women with RPL were 
significantly higher than in the controls (14.0 [8.0-20.0] 
vs. 9.0 [6.0-12.0] ng/ml,  p = 0.043) (Fig. 1).  In addition,  
plasma levels of βTG in the RPL group were signifi-
cantly higher than in the controls (42.0 [24.3-59.8] vs. 
31.5 [26.6-36.4] ng/ml,  p = 0.002) (Fig. 2).
Coagulative risk factors in RPL. The normal 
value of each coagulative risk factor of RPL and the fre-
quency of positivity for each coagulative risk factor in 
the RPL group are shown in Table 2.  Correlations 
between positivity for each coagulative risk factor and 
positivity for PF4/βTG are shown in Table 3.  The chi-
square test showed no significant correlations between 
positivity for PF4 and positivity for any of the risk fac-
tors.  However,  there was a significant association 
between positivity for βTG and positivity for aPE IgM 
(p = 0.048).  Eighteen of the women in the RPL group 
who were positive for PF4 (18/40; 45%) were negative 
for all coagulative risk factors.  Similarly,  18 of the 
women in the RPL group who were positive for βTG 
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Fig. 1　 Comparison of plasma levels of PF4 between the controls 
and women with RPL.  Plasma levels of PF4 in the RPL group were 
significantly higher than in controls (14.0 [8.0-20.0] vs. 9.0 [6.0-
12.0] ng/ml,  p＝0.043).
RPL,  recurrent pregnancy loss; PF4,  platelet factor 4.
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Fig. 2　 Comparison of plasma levels of βTG between the con-
trols and women with RPL.  Plasma levels of βTG in the RPL group 
were significantly higher than in controls (42.0 [24.3-59.8] vs. 31.5 
[26.6-36.4] ng/ml,  p＝0.002).
RPL,  recurrent pregnancy loss; βTG,  β-thromboglobulin.
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Table 3　 Correlations between coagulative risk factors and PF4/βTG in RPL
Risk factors PF4 positivity,  n (%) P value βTG positivity,  n (%) P value
LAC 0 (0.0) 0 (0.0)
aCL IgG 3 (7.5) 0.50 4 (8.2) 0.49　　
aCL IgM 2 (5.0) 0.38 2 (4.1) 0.58　　
aPE IgG 4 (10) 0.20 4 (8.2) 0.053　　
aPE IgM 11 (28) 0.059 13 (27) 0.048＊＊
Protein S deficiency 2 (5.0) 0.93 2 (4.1) 0.74　　
Protein C deficiency 0 (0.0) 0.54 0 (0.0) 0.47　　
FXII deficiency 7 (18) 0.79 12 (25) 0.22　　
All negatives 18 (45) 18 (37)
Total 40 49
Correlations between positivity for coagulative risk factors and positivity for PF4/βTG are shown.
A chi-square test was used to indicate correlations between variables.  There were no significant correlations between positivity for PF4 and 
positivity for all risk factors.  There were no significant correlations between positivity for βTG and positivity for each factor; LAC,  aCL IgG,  
aCL IgM,  aPE IgG,  Protein S deficiency,  Protein C deficiency and FXII deficiency.  There was a significant association between positivity 
for βTG and positivity for aPE IgM (p＝0.048).  Eighteen of the PF4-positive women with RPL (45%) were negative all risk factors.  
Eighteen of the βTG-positive women with RPL (37%) were negative for all risk factors.
PF4,  platelet factor 4; βTG,  β-thromboglobulin; RPL,  recurrent pregnancy loss; LAC,  lupus anticoagulant; aCL IgG,  anti-cardiolipin 
antibody immunoglobulin G; aCL IgM,  anti-cardiolipin antibody immunoglobulin M; aPE IgG,  anti-phosphatidylethanolamine antibody 
immunoglobulin G; aPE IgM,  anti-phosphatidylethanolamine antibody immunoglobulin M; FXII,  coagulation factors XII.
PF4 positivity: PF4＞＝20 ng/ml; βTG positivity: βTG＞＝50 ng/ml.
Table 2　 Frequency of positivity for coagulative risk factors in RPL
Normal value Positivity in RPL,  n＝135 (%)
LAC ＜1.2 0 (0.0)
aCL IgG ＜10 U/ml 14 (10)
aCL IgM ＜8 U/ml 4 (3.0)
aPE IgG ＜0.3 22 (16)
aPE IgM ＜0.45 24 (18)
Protein S activity or antigen ＞60% 7 (5.2)
Protein C activity ＞60% 1 (0.7)
FXII ＞60% 26 (19)
The normal value of each coagulative risk factor for RPL and the frequency of positivity for each coagulative risk factor in the women with 
RPL are shown.  RPL,  recurrent pregnancy loss; LAC,  lupus anticoagulant; aCL IgG,  anti-cardiolipin antibody immunoglobulin G; aCL 
IgM,  anti-cardiolipin antibody immunoglobulin M; aPE IgG,  anti-phosphatidylethanolamine antibody immunoglobulin G; aPE IgM,  
anti-phosphatidylethanolamine antibody immunoglobulin M; FXII,  coagulation factors XII.
Table 1　 Characteristics and clinical findings of the women with RPL and controls
Controls (n＝28) RPL (n＝135) P value
Age (year) 34.3±5.3 34.3±5.0 0.91
BMI 20.6±2.5 21.0±2.7 0.79
Parity (number of pregnancy losses ＜at 12 wks) 0 2.5±0.8
Data are presented as means ± 1 standard deviation. Studentʼs t-test was used to compare differences between the groups. A p value of 
＜0.05 was accepted as statistically significant.  There were no statistically significant differences between controls and the RPL group in 
regard to age and BMI (body mass index).
RPL,  recurrent pregnancy loss; BMI,  body mass index.
(18/49,  37%) were also negative for all coagulative risk 
factors (Table 3).
Discussion
The present study demonstrated that plasma levels of 
PF4 and βTG were higher in women with RPL than in 
women who had never experienced pregnancy losses.  
Another interesting finding is that there were some 
women with RPL who were positive for plasma PF4 
and/or βTG but did not show any increase in the levels 
of known coagulating risk factors for RPL.
Increased levels of PF4 and βTG reflect increased 
platelet activation in vivo.  Platelets are activated through 
several receptor-mediated pathways [8].  In the denuded 
area of the vascular endothelium,  collagen stimulates 
platelet activation and adhesion to the vessel wall [8].  
Activated platelets extrude granule contents,  including 
PF4,  βTG,  adenosine diphosphate,  calcium,  serotonin 
and so on,  and induce irreversible platelet-platelet 
aggregation and thrombus formation [8].  Many studies 
have shown that increased plasma levels of PF4 and βTG 
in patients with diseases related to vascular endothelial 
dysfunction such as atherosclerosis,  coronary artery,  
cerebrovascular and peripheral vascular diseases,  and 
diabetic vascular disease [7-12].  Elevated PF4 and βTG 
have also been reported in patients with inflammatory 
diseases such as rheumatic arthritis,  atopic dermatitis,  
asthma and inflammatory bowel diseases [13-17].  
Platelets are now recognized as key players in inflam-
matory and innate immune responses [18].  
Chemokines such as PF4 and βTG derived from plate-
lets may play an important role in inflammation by 
attracting and stimulating leukocytes [19].  These 
chemokines regulate leukocyte movement,  migration,  
and other proinflammatory functions such as phagocy-
tosis and generation of reactive oxygen species [18].
With respect to obstetrics,  PF4 and βTG levels were 
reported to be significantly higher in women with pre-
eclampsia than women with uncomplicated pregnancy 
[20 , 21].  However,  there has been nor prior report of 
increases in PF4 and βTG in women with RPL,  and our 
present results thus suggest the importance of measure-
ment of PF4 and βTG even in the absence of coagula-
tive risk factors.  It is known that the hemostatic balance 
changes in the direction of hypercoagulability during 
pregnancy [22 , 23].  Thrombosis in the decidual vessels 
is believed to be one possible cause of recurrent preg-
nancy loss [24].  A previous study showed that patients 
with RPL exhibited greater platelet aggregation in 
response to arachidonic acid than controls [5].  Other 
studies have demonstrated increased levels of throm-
bin-antithrombin complexes [6],  and increased endo-
thelial microparticles in women with a history of RPL,  
suggesting that endothelial damage or activation might 
be associated with the pathogenesis of pregnancy loss,  
and the prothrombotic state of thromboelastography in 
RPL [24 , 25].  These studies support our hypothesis that 
some women with RPL might be in a chronic subclini-
cal hypercoagulable status before pregnancy and platelet 
activation may pose a risk for thrombosis in decidual 
vessels.
Platelet-activating factor (PAF; 1-0-alkyl-2-acetyl-
sn-glycero-3-phosphocholine) is related to platelet acti-
vation [26],  induces secretion of PF4 [27 , 28],  and plays 
an important role for maintenance of pregnancy [28].  
Eser et al.  reported that PAF levels were elevated in 
patients with RPL [29].  In their study,  levels of serum 
PAF were significantly higher in women with recurrent 
miscarriage,  although they did not evaluate the direct 
association between PAF and the platelet activation 
[29].  Some of the women with RPL with an increased 
level of PF4/βTG had positive coagulative risk factors,  
indicating that platelet activation plays an important 
role in the process of miscarriage,  leading to RPL.
Among the coagulative risk factors analyzed in our 
study,  only the aPE IgM level was elevated in women 
with RPL who had an increased level of βTG,  suggest-
ing that aPE IgM might be one of the factors causing 
platelet activation in RPL.  Some studies have reported 
that aPE is significantly associated with fetal loss and/or 
thrombosis,  and that aPE may be responsible for clini-
cal features that are highly suggestive of APS [30 , 31].  
aPE IgM is found more frequently in women with 
unexplained RPL compared to women who have expe-
rienced only normal pregnancy or those with explained 
RPL [30-32].  Some studies supported the role of aPE is 
to maintain placental homeostasis [33].  However,  
well-controlled prospective studies will be needed to 
elucidate the relationship between aPE and thrombotic 
diseases [31].  A previous study in which platelet aggre-
gation induced by γ-thrombin was measured with a 
laser light scattering aggregometer reported that platelet 
aggregation was caused by aPE in women with RPL 
[34].  Together with the findings of the present study,  
these facts suggest that aPE IgM could be one of the risk 
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factors for RPL through platelet activation.
Our study did not show any significant correlations 
between PF4/βTG and any of the coagulative risk fac-
tors of RPL except aPE IgM.  LAC,  aCL IgG and aCL 
IgM are well known to be diagnostice of APS and to be 
risk factors for RPL [35].  The pathogenic mechanisms 
of aCL on negatively charged phospholipids located on 
the outer leaflet of the plasma membrane include blood 
coagulation or thrombosis and direct effects against 
trophoblasts [36].
Protein C deficiency and protein S deficiency result 
in loss of inactivation against activated factor V (aFV) 
[35].  None of the coagulative risk factors except aPE 
was correlated with platelet activation in this study,  and 
it may be possible that pregnancy losses are caused by 
pathways other than platelet activation.
FXII plays a key role in coagulation and fibrinolytic 
processes [36].  FXII deficiency results in suppression of 
the fibrinolytic system and thereby causes thrombosis 
[37].  In previous studies,  an association of FXII defi-
ciency with RPL has been reported [36 , 38 , 39].  Our 
study showed that subjects with lower levels of FXII 
tended to have higher rates of positivity for PF4/βTG.  
However,  this association did not reach the level of sta-
tistical significance.  Studies employing larger numbers 
of subjects may be necessary in order to clarify the 
potential association between FXII and PF4/βTG.
Our study showed that 18 subjects who were positive 
for either PF4 or βTG were negative for coagulative risk 
factors of RPL.  This finding indicates that there might 
be other unknown factors that cause platelet activation 
in RPL.
In RPL,  an important question is whether women 
with RPL are in the platelet activation stage before and/
or during pregnancy.  If RPL patients are in a platelet- 
activated stage before pregnancy,  they may be indicated 
for prophylactic anticoagulant therapy to avoid sponta-
neous abortions at next pregnancy.  Aspirin inhibits 
platelet aggregation,  and improves the levels of PF4 and 
βTG in many occlusive vascular diseases [7 , 40].  In 
obstetrics,  aspirin is considered to reduce placental 
coagulation as a platelet inhibitor and to contribute to 
successful placental development [4].  Moreover,  aspi-
rin is known to help improve uterine perfusion [41].  
Two randomized controlled studies showed that there 
were no differences in live birth rates and pregnancy 
complications among anticoagulant treatments (i.e,  
enoxaparin,  aspirin,  or both) [42 , 43].  These studies 
found that both the aspirin and enoxaparin treatments 
were associated with a high live birth rate and few late 
pregnancy complications respectively.  However,  the 
effectiveness of prophylactic antithrombotic therapy for 
unexplained RPL has been a subjects of controversy 
[44].  A recent trial failed to support any role of aspirin 
in unexplained RPL [45].  However,  in regard to the 
above findings,  it should be noted that the unexplained 
RPL groups could have included both patients with 
unknown coagulative factors and patients who do not 
have any coagulative risk factors.  If women with RPL 
are in the platelet-activated stage,  prophylactic anti-
thrombotic therapies could be one of the options to 
avoid pregnancy losses.  If we could identify increased 
platelet activation,  it might guide therapy in individual 
patients.  Thus,  measurements of PF4 and βTG would 
be useful to determine whether antithrombotic therapy 
is necessary in cases of unexplained RPL.  Also,  mea-
surements of PF4/βTG are more convenient and less 
expensive than measurements of antiphospholipid anti-
bodies and other coagulative risk factors of RPL.  Since 
there were a considerable number of women with RPL 
who showed negative coagulative risk factors of RPL in 
our study,  it may be important to assess platelet activa-
tion in RPL.
Elevated PF4 and βTG were observed in several 
women of the control group.  We consider that healthy 
women also could show platelet activation,  because PF4 
and βTG are elevated by subclinical damage of the vas-
cular endothelium [8].  In our study,  PF4 and βTG were 
elevated when blood samples were collected in appro-
priately.  Thus PF4 and βTG may be sensitive markers of 
prethrombotic states and thrombosis.
Several limitations must be considered when inter-
preting our findings.  First,  our study may not have had 
a sufficient sample size to detect significant correlations 
between PF4/βTG and coagulative risk factors of RPL.  
Second,  we could not investigate coagulative risk fac-
tors in the controls,  and therefore our study could not 
demonstrate the clinical meanings and risks of the coag-
ulative risk factors in this study.  Third,  we did not mea-
sure the levels of PF4 and βTG after the antithrombotic 
therapy,  observe the obstetric prognosis of subjects or 
verify the effectiveness of antithrombotic therapy in this 
study; further investigation of these issues in random-
ized controlled trials will be needed.
In conclusion,  this is the first study to demonstrate 
higher plasma levels of PF4 and βTG in women with 
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RPL compared to those without.  In addition,  our study 
found that elevated levels of PF4 and βTG were signifi-
cant correlated with the presence of aPE IgM.  Also,  
there were some women with RPL who were positive 
only for plasma PF4 and/or βTG,  and not for any of the 
other known coagulating risk factors for RPL.  Thus 
there may be other factors related to platelet activation 
and leading to miscarriage.  Therefore,  measurements 
of PF4 and βTG be important because they help identify 
women who are at risk of RPL.  Further studies are nec-
essary to investigate unknown factors that contribute to 
platelet activation and thereby to RPL.
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